Approaches to determining tolerance of intensive chemotherapy treatment
Approach . | Characteristics . | Evidence . | Nature of the study . |
---|---|---|---|
Geriatric assessment | Multidimensional assessment | Cognition, physical function, emotional health, and comorbidity burden correlate with mortality | Single-center and small multicenter prospective studies3,5,7 |
Ferrara criteria | Mostly age, comorbidities, and ECOG PS | Criteria-defined fitness correlates with mortality | Retrospective studies10,11 |
Comorbidity Index | Mostly comorbidities | Higher comorbidity burden correlates with mortality | Retrospective and prospective studies12 |
Mortality scores∗ (several) | Age, performance status, laboratory data, etc | Higher score correlates with mortality | Post hoc analysis of trials and retrospective studies9,13-15 |
Approach . | Characteristics . | Evidence . | Nature of the study . |
---|---|---|---|
Geriatric assessment | Multidimensional assessment | Cognition, physical function, emotional health, and comorbidity burden correlate with mortality | Single-center and small multicenter prospective studies3,5,7 |
Ferrara criteria | Mostly age, comorbidities, and ECOG PS | Criteria-defined fitness correlates with mortality | Retrospective studies10,11 |
Comorbidity Index | Mostly comorbidities | Higher comorbidity burden correlates with mortality | Retrospective and prospective studies12 |
Mortality scores∗ (several) | Age, performance status, laboratory data, etc | Higher score correlates with mortality | Post hoc analysis of trials and retrospective studies9,13-15 |
ECOG PS, Eastern Cooperative Oncology Group Performance Status.
These scoring systems do not directly measure fitness but provide the risk of early mortality associated with the use of intensive chemotherapy.